Assertio (NASDAQ:ASRT) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of Assertio (NASDAQ:ASRT) from a buy rating to a hold rating in a research note issued to investors on Monday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Assertio in a research report on Monday, December 16th.

Assertio Trading Up 1.0 %

NASDAQ:ASRT opened at $0.73 on Monday. The stock’s 50 day moving average price is $0.81 and its 200 day moving average price is $0.96. Assertio has a 52 week low of $0.68 and a 52 week high of $1.80. The company has a market capitalization of $69.63 million, a P/E ratio of -1.00, a P/E/G ratio of 3.25 and a beta of 0.81. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01.

Hedge Funds Weigh In On Assertio

Several hedge funds have recently added to or reduced their stakes in ASRT. Geode Capital Management LLC boosted its holdings in Assertio by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company’s stock worth $955,000 after buying an additional 21,059 shares during the last quarter. Two Sigma Investments LP raised its position in Assertio by 3.9% in the 4th quarter. Two Sigma Investments LP now owns 910,046 shares of the company’s stock valued at $793,000 after buying an additional 34,004 shares during the last quarter. Empowered Funds LLC increased its position in shares of Assertio by 5.4% during the 4th quarter. Empowered Funds LLC now owns 455,282 shares of the company’s stock worth $397,000 after purchasing an additional 23,369 shares during the last quarter. CM Management LLC increased its position in shares of Assertio by 23.1% during the 4th quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $348,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Assertio by 21.3% during the 4th quarter. Northern Trust Corp now owns 227,217 shares of the company’s stock worth $198,000 after purchasing an additional 39,906 shares during the last quarter. Institutional investors own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.